Stimulant vs Non-Stimulant ADHD Medication: How to Decide

Stimulants (methylphenidate and amphetamine products) usually work faster and have a larger average effect than non-stimulants. For school-age children, the American Academy of Pediatrics puts the effect size at about 1.0 for stimulants and 0.7 for non-stimulants. Non-stimulants (atomoxetine, viloxazine, and extended-release guanfacine and clonidine) are not controlled substances, take longer to judge, and are often the better choice when misuse, diversion or stimulant side effects are a concern.

Neither class is right for everyone. The decision weighs how much benefit you need, how quickly, your heart and mental health history, who else lives with you, and the practical burden of controlled-substance prescriptions.

Side-by-side comparison

How fast they work and how a dose is found

Stimulants work within hours of a dose. In a classroom study of children ages 6 to 12 described in the lisdexamfetamine label, the drug's effect on behavior was statistically significant from 2 to 12 hours after a morning dose, though not at 1 hour. That same-day effect lets a prescriber judge each dose quickly and adjust it in steps. Response is individual: in school-age children, the AAP notes that about 40% respond to both methylphenidate and amphetamine and about 40% respond to only one of them, so a poor result on one stimulant does not mean stimulants will not work.

Non-stimulants need patience. Atomoxetine's label, for example, says that if the response at the usual target dose is not optimal after 2 to 4 additional weeks, the dose may then be raised to the maximum. That slower timeline is a drawback for someone who needs help this semester, and an advantage for someone who wants steady, all-day coverage without peaks and wear-off.

Formulation and the shape of your day

Within the stimulant class, the formulation matters as much as the molecule. Short-acting tablets give a few hours of coverage and can be timed around demanding tasks; extended-release products are designed to last through a school or work day with one morning dose. If a dose wears off before homework, an evening commute or family time, or lasts so long that it disturbs sleep, that is a reason to adjust the formulation or timing with your prescriber, not to conclude that the medication failed. Non-stimulants, by contrast, are taken daily and are not timed around particular hours.

How guidelines order the choices for adults

US labels set what each medication is approved for, but they do not rank the options. The UK's NICE guideline does, and its sequence for adults is a useful reference point for how many clinicians think:

1. Offer lisdexamfetamine or methylphenidate first.
2. If a 6-week trial of one at an adequate dose has not helped enough, consider switching to the other.
3. Offer atomoxetine if a person cannot tolerate either stimulant, or if symptoms have not responded to separate 6-week trials of both, having considered other preparations and adequate doses.
4. Get a second opinion or specialist referral if symptoms have not responded to one or more stimulants and one non-stimulant.

NICE also says guanfacine should not be offered to adults without advice from a specialist ADHD service, noting that this is off-label use. In the US, viloxazine has an adult indication that the UK guideline does not address. The comparisons in methylphenidate versus amphetamine and Qelbree versus Strattera go a level deeper within each class.

Side effects and safety screening

Both classes affect the cardiovascular system, in different directions. The AAP describes increased heart rate and blood pressure with atomoxetine and decreased heart rate and blood pressure with guanfacine and clonidine. Before starting a stimulant, the guideline asks about personal cardiac symptoms and a family history of sudden death, cardiovascular symptoms and inherited heart conditions, and the lisdexamfetamine label advises avoiding use in people with serious heart disease and monitoring blood pressure and pulse.

Mental health history matters too. The lisdexamfetamine label asks prescribers to screen for risk factors for mania before starting. Atomoxetine carries a Boxed Warning about suicidal thoughts in pediatric patients, viloxazine carries one for all patients, and atomoxetine should be stopped if signs of liver injury appear. Viloxazine also cannot be combined with MAO inhibitors or certain drugs processed by the liver enzyme CYP1A2. Bring a full medication and supplement list to the visit.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

Anxiety, tics and other conditions

A common assumption is that anyone with anxiety or tics should avoid stimulants. The guidance is more nuanced. NICE recommends offering the same medication choices to people with ADHD and an anxiety disorder, a tic disorder or autism as to other people with ADHD. If tics appear on a stimulant, it advises first considering whether they are actually related to the medication, since tics naturally wax and wane, and whether the impairment from the tics outweighs the benefit of treatment. If they are stimulant related, the options include reducing the dose, changing medication or stopping.

Other situations call for more caution:

• Mania or psychosis: NICE advises stopping ADHD medication during an acute psychotic or manic episode and reconsidering it after the episode resolves.
• Sleep: NICE suggests monitoring changes in sleep, for example with a sleep diary, and adjusting medication accordingly.
• Binge eating disorder: lisdexamfetamine is also FDA-approved for moderate to severe binge eating disorder in adults, but its label states it is not indicated or recommended for weight loss. See binge eating disorder treatment options.

When ADHD and anxiety or depression occur together, deciding what to treat first is its own question; ADHD and anxiety together and ADHD and depression together cover it.

Monitoring once you start

Whichever class you take, follow-up visits include some routine checks. These are set by your prescriber; the list below shows what guidance and labels describe.

For the cardiovascular side in more detail, see ADHD medication and your heart.

Misuse, diversion and the 2023 warning

In 2023 the FDA required all prescription stimulants to carry a consistent Boxed Warning on misuse, abuse, addiction and overdose, and asked prescribers to assess each patient's risk before prescribing and monitor throughout treatment. The agency noted that most people who misuse prescription stimulants get them from family members or peers.

That is why household matters. For adolescents, the AAP describes diversion as a special concern, advises watching refill requests, and says clinicians may consider non-stimulants that minimize abuse potential, such as atomoxetine and extended-release guanfacine or clonidine. Whatever you take, store it securely and never share it.

Prescription logistics in New York

Because stimulants are Schedule II, the paperwork is heavier than for most medicines:

• Schedule II prescriptions cannot be refilled; each fill needs a new prescription.
• A prescriber may issue several dated prescriptions totaling up to a 90-day supply only under specific conditions, including that state law permits it.
• New York prescribers must check the state prescription monitoring program registry before prescribing a Schedule II, III or IV controlled substance, with limited exceptions.

Expect regular visits and new prescriptions rather than automatic refills. Non-stimulants are written like most other prescriptions. If you are changing prescribers, plan the handoff so you do not run out; see switching psychiatrists without a gap.

Telehealth prescribing

Prescribing controlled substances by telemedicine is governed by federal DEA rules. Since the COVID-19 pandemic, the DEA and HHS have extended temporary telemedicine flexibilities; the current, fourth extension is effective from January 1 through December 31, 2026. What replaces it after that date was still being settled when this article was updated, so ask your prescriber how any change would affect your visits. Atomoxetine, guanfacine ER and clonidine ER are not controlled substances, so these particular rules do not apply to them. Dr. Lewis's practice sees patients by telehealth only when they are physically located in a state where the clinician holds an active license. Telehealth versus in-person psychiatry covers the trade-offs.

Stimulant shortages

Supply problems have not fully cleared. As of October 2026, the FDA's drug shortage database still listed mixed amphetamine salts tablets, lisdexamfetamine capsules and chewable tablets, and extended-release methylphenidate tablets as current shortages, with the amphetamine salts listing dating back to October 2022. Availability varies by strength, manufacturer and pharmacy, and changes week to week.

Practical steps: call your pharmacy a few days before you need a fill, ask whether another strength or manufacturer is in stock, and let your prescriber know early if a fill fails. Do not ration, skip or switch doses on your own; your prescriber can decide whether a different formulation or a non-stimulant makes sense.

When the first choice does not work

A disappointing first trial is common and rarely the end of the road. Prescribers usually work through a few questions, in roughly this order, before concluding that a class has failed:

1. Was the dose adequate, and was it taken consistently?
2. Does the formulation match your day, or is it wearing off early or lasting too long?
3. Is another stimulant from the other family worth trying? In school-age children, about 40% respond to only one of methylphenidate or amphetamine.
4. Would a non-stimulant, or a non-stimulant added to a stimulant, suit the problem better?
5. Is something else contributing, such as sleep problems, anxiety, depression or substance use?

If you are on a stimulant that you cannot fill, what to do during an ADHD medication shortage has practical steps. If two medications in a row have not helped, a second opinion on your medication can be worthwhile.

Who may do better on a non-stimulant

• People with a current or past substance use disorder, or a household where diversion is a risk.
• People whose anxiety, insomnia, appetite loss or irritability worsened on stimulants.
• People with heart conditions that make stimulants inadvisable, after cardiac review.
• People who want smooth all-day coverage, including evenings, without timing doses.
• People who have had repeated trouble filling stimulant prescriptions.

Stimulants are usually tried first when the goal is the largest, fastest improvement and there are no safety barriers. Combinations exist too: guanfacine ER and clonidine ER are approved as add-ons to stimulants as well as on their own. For adults, the broader set of options, including CBT and coaching, is in adult ADHD treatment options compared.

FDA-approved ages: children vs adults

The stimulant labels above say use is not recommended in children under 6. For young children, guideline-recommended treatment starts with behavioral approaches; see preparing your child for an ADHD evaluation.

Pregnancy and breastfeeding

If you are pregnant, planning a pregnancy or breastfeeding, tell your prescriber before starting or continuing any ADHD medication. The lisdexamfetamine label, for example, says available data are not sufficient to inform a drug-associated risk of major birth defects or miscarriage, notes a pregnancy exposure registry for ADHD medications, and advises against breastfeeding while taking it. Other medications have their own label language, and these decisions are made with your prescriber and obstetric clinician. Psychiatric medications during pregnancy and psychiatric medications while breastfeeding set out the questions to ask.

Children and teens: where medication fits

For children, the AAP guideline sets the role of medication by age, and behavioral treatment is part of the plan at every stage:

The AAP notes that no non-stimulant has had enough rigorous study in 4- and 5-year-olds to be recommended at that age. Before a non-stimulant, it also recommends taking a personal and family cardiac history and doing further evaluation, such as an ECG, if risk factors are present. NICE likewise lists methylphenidate first for children 5 and over, with atomoxetine or guanfacine offered if stimulants are not tolerated or have not worked. School supports such as a 504 plan or IEP and parent training are part of treatment, not extras.

What the evidence does not settle

• Which medication will work for you. Average effect sizes compare groups; individual response varies, which is why a second stimulant is often tried before switching class.
• Head-to-head answers for every pair. Many comparisons between specific products, especially in adults, rest on limited direct evidence.
• How guidelines from different countries map onto US approvals. NICE's ordering reflects UK licensing; the FDA labels described here govern US use.
• Long-term choices made once. ADHD treatment is usually adjusted over years as school, work, health and family circumstances change.

Before the first prescription: what to have ready

A prescriber choosing between classes needs a few facts that are easy to gather ahead of time:

• Any heart symptoms, such as fainting, chest pain or palpitations with exercise, and any family history of sudden death or inherited heart conditions.
• A full list of current medications and supplements, including any MAO inhibitor taken recently, since viloxazine cannot be combined with MAO inhibitors.
• Any personal or family history of bipolar disorder or mania.
• Honest information about alcohol, cannabis and other substance use, and whether anyone in your household might misuse a stimulant.
• Pregnancy plans or breastfeeding.
• Any ADHD medication you have taken before, with the dose and what happened. How to prepare your medication history has a template.

Questions to bring to your prescriber

• Given my history, which class would you start with, and why?
• What benefit should I notice, and by when, before we change course?
• Which side effects are expected and temporary, and which should I report right away?
• What heart rate and blood pressure checks will we do, and how often?
• How will prescriptions and follow-up visits work, and what happens if a pharmacy is out of stock?
• If I want to stop, how should that be done?

Write down your baseline before starting: the tasks you struggle with, sleep, appetite and mood. Comparing against that baseline after each change makes follow-up visits more productive, and a family member's observations can confirm whether the change is visible to others. The article on ongoing medication management describes what those visits usually cover.

How the practice approaches the decision

At the practice, medication is one possible part of an ADHD plan, alongside lifestyle changes, nutrition, psychotherapy and executive-function coaching, and is used when appropriate. Its prescribers include psychiatrists and psychiatric nurse practitioners. The practice explains its prescribing philosophy in low-dose ADHD medication and its medication management page; if a current medication has stopped helping, see when ADHD medication stops working. Diagnosis comes first, as described in the practice's ADHD assessment, and the guide to choosing psychiatric care covers the rest.

Frequently asked questions

Can I switch from a stimulant to a non-stimulant on my own?

No. Talk to your prescriber first. Some non-stimulants take weeks to judge, guanfacine and clonidine must be tapered when stopped, and your prescriber needs to plan the overlap and monitoring.

Can stimulants and non-stimulants be taken together?

Sometimes. Guanfacine ER and clonidine ER are FDA-approved as add-on treatment to stimulants as well as on their own. Your prescriber decides whether a combination fits your situation.

Do non-stimulants have a risk of addiction?

Atomoxetine and guanfacine ER are not controlled substances, and the Intuniv label states it has no known potential for abuse or dependence. They have other risks, so they still need monitoring.

What should I do if my pharmacy cannot fill my stimulant?

Ask whether another strength, manufacturer or nearby pharmacy has it, and contact your prescriber promptly. Do not stretch doses or stop on your own; the prescriber can decide on an alternative.

Is a heart test required before starting ADHD medication?

Not routinely for everyone. Prescribers take a personal and family cardiac history and check blood pressure and pulse, and may order an ECG or cardiology review if risk factors are present.

Do stimulants make tics worse?

Not necessarily. UK guidance recommends offering people with tic disorders the same ADHD medication choices as anyone else, and if tics appear, first checking whether they are related to the medication, because tics naturally come and go. Your prescriber can adjust the plan if they are.

Can I be prescribed a stimulant by telehealth?

Temporary federal flexibilities allow telemedicine prescribing of controlled medications through December 31, 2026. What follows has not been finalized, and your prescriber must also be able to see you in the state where you are located, so ask how it works for you.

How long should a medication trial last before switching?

It depends on the medication. Stimulant doses are typically adjusted in steps about a week apart, while non-stimulants such as atomoxetine take weeks to judge. UK guidance describes 6-week trials at an adequate dose before switching between first-line options in adults.

Sources

1. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. American Academy of Pediatrics, Pediatrics 144(4):e20192528, 2019. pmc.ncbi.nlm.nih.gov
2. Vyvanse (lisdexamfetamine dimesylate) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
3. Strattera (atomoxetine) prescribing information. Eli Lilly and Company / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
4. Concerta (methylphenidate HCl extended-release tablets) prescribing information. Janssen Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
5. Adderall XR (mixed amphetamine salts extended-release) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2026. dailymed.nlm.nih.gov
6. Intuniv (guanfacine extended-release tablets) prescribing information. Takeda Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
7. FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions. U.S. Food and Drug Administration (Drug Safety Communication), 2023. fda.gov
8. Qelbree (viloxazine extended-release capsules) prescribing information. Supernus Pharmaceuticals / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
9. Clonidine hydrochloride extended-release tablets prescribing information. Somerset Therapeutics / DailyMed (NLM), 2025. dailymed.nlm.nih.gov
10. 21 CFR 1306.12 Refilling prescriptions; issuance of multiple prescriptions. Electronic Code of Federal Regulations (DEA), 2026. ecfr.gov
11. New York Public Health Law Section 3343-A (prescription monitoring program registry). New York State Senate, 2025. nysenate.gov
12. FDA Drug Shortages Database (amphetamine mixed salts tablets; lisdexamfetamine capsules; methylphenidate ER tablets). U.S. Food and Drug Administration, 2026. dps.fda.gov
13. Drugs@FDA: Qelbree (viloxazine hydrochloride), NDA 211964. U.S. Food and Drug Administration, 2022. accessdata.fda.gov
14. Attention deficit hyperactivity disorder: diagnosis and management (NG87), Recommendations. National Institute for Health and Care Excellence, 2019. nice.org.uk
15. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Drug Enforcement Administration and HHS, Federal Register, 2025. federalregister.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.